Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC

Gastroenterology

Volumn 130, Issue 4, 2006, Pages 1117-1128

  Calvisi, Diego F ^a   Ladu, Sara ^a   Gorden, Alexis ^a   Farina, Miriam ^a   Conner, Elizabeth A ^a   Lee, Ju Seog ^a   Factor, Valentina M ^a   Thorgeirsson, Snorri S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE; JANUS KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NORE1A PROTEIN; PICEATANNOL; PROTEIN; PROTEIN TYROSINE PHOSPHATASE SHP 1; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RAS PROTEIN; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 2; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG; UO 126; ZEBULARINE;

ADULT; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA METHYLATION; DNA SEQUENCE; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GENE INACTIVATION; GENE REPRESSION; GENOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MICROSATELLITE MARKER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 33645976174     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.01.006     Document Type: Article

References (57)

1. Bruix J., Boix L., Sala M., and Llovet J.M. Focus on hepatocellular carcinoma. Cancer Cell 5 (2004) 215-219
2. Thorgeirsson S.S., and Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31 (2004) 339-346
3. Feo F., Pascale R.M., Simile M.M., De Miglio M.R., Muroni M.R., and Calvisi D. Genetic alterations in liver carcinogenesis. implications for new preventive and therapeutic strategies. Crit Rev Oncog 11 (2000) 19-62
4. Shields J.M., Pruitt K., McFall A., Shaub A., and Der C.J. Understanding Ras. "it ain't over 'til it's over.". Trends Cell Biol 10 (2000) 147-154
5. Bar-Sagi D., and Hall A. Ras and Rho GTPases. a family reunion. Cell 103 (2000) 227-238
6. Johnson G.L., and Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298 (2002) 1911-1912
7. Feig L.A., and Buchsbaum R.J. Cell signaling. life or death decisions of ras proteins. Curr Biol 12 (2002) 259-261
8. Cox A.D., and Der C.J. The dark side of Ras. regulation of apoptosis. Oncogene 22 (2003) 8999-9006
9. Johnston A.M., Naselli G., Gonez L.J., Martin R.M., Harrison L.C., and DeAizpurua H.J. SPAK, a STE20/SPS1-related kinase that activates the p38 pathway. Oncogene 19 (2000) 4290-4297
10. Ura S., Masuyama N., Graves J.D., and Gotoh Y. MST1-JNK promotes apoptosis via caspase-dependent and independent pathways. Genes Cells 6 (2001) 519-530
11. Khokhlatchev A., Rabizadeh S., Xavier R., Nedwidek M., Chen T., Zhang X.F., Seed B., and Avruch J. Identification of a novel Ras-regulated proapoptotic pathway. Curr Biol 12 (2002) 253-265
12. 2+ pump 4b and the proapoptotic tumor suppressor Ras-associated factor 1 (RASSF1). J Biol Chem 279 (2004) 31318-31328
13. Bromberg J.F. Activation of STAT proteins and growth control. Bioessays 23 (2001) 161-169
14. Kisseleva T., Bhattacharya S., Braunstein J., and Schindler C.W. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285 (2002) 1-24
15. Wormald S., and Hilton D.J. Inhibitors of cytokine signal transduction. J Biol Chem 79 (2004) 821-824
16. Krebs D.L., and Hilton D.J. SOCS proteins. negative regulators of cytokine signaling. Stem Cells 19 (2001) 378-387
17. Larsen L., and Ropke C. Suppressors of cytokine signalling. SOCS. APMIS 110 (2002) 833-944
18. Yang B., Guo M., Herman J.G., and Clark D.P. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 163 (2003) 1101-1107
19. Lee S., Lee H.J., Kim J.H., Lee H.S., Jang J.J., and Kang G.H. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 163 (2003) 1371-1378
20. Dammann R., Li C., Yoon J.H., Chin P.L., Bates S., and Pfeifer G.P. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25 (2000) 315-319
21. Kuzmin I., Gillespie J.W., Protopopov A., Geil L., Dreijerink K., Yang Y., Vocke C.D., Duh F.M., Zabarovsky E., Minna J.D., Rhim J.S., Emmert-Buck M.R., Linehan W.M., and Lerman M.I. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res 62 (2002) 3498-3502
22. Dreijerink K., Braga E., Kuzmin I., Geil L., Duh F.M., Angeloni D., Zbar B., Lerman M.I., Stanbridge E.J., Minna J.D., Protopopov A., Li J., Kashuba V., Klein G., and Zabarovsky E.R. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci U S A 98 (2001) 7504-7509
23. Burbee D.G., Forgacs E., Zochbauer-Muller S., Shivakumar L., Fong K., Gao B., Randle D., Kondo M., Virmani A., Bader S., Sekido Y., Latif F., Milchgrub S., Toyooka S., Gazdar A.F., Lerman M.I., Zabarovsky E., White M., and Minna J.D. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93 (2001) 691-699
24. Fukushima N., Sato N., Sahin F., Su G.H., Hruban R.H., and Goggins M. Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer 89 (2001) 338-343
25. Nagai H., Kim Y.S., Lee K.T., Chu M.Y., Konishi N., Fujimoto J., Baba M., Matsubara K., and Emi M. Inactivation of SSI-1, a JAK/STAT inhibitor, in human hepatocellular carcinomas, as revealed by two-dimensional electrophoresis. J Hepatol 34 (2001) 416-421
26. Yoshikawa H., Matsubara K., Qian G.S., Jackson P., Groopman J.D., Manning J.E., Harris C.C., and Herman J.G. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 28 (2001) 29-35
27. Nagai H., Kim Y.S., Konishi N., Baba M., Kubota T., Yoshimura A., and Emi M. Combined hypermethylation and chromosome loss associated with inactivation of SSI-1/SOCS-1/JAB gene in human hepatocellular carcinomas. Cancer Lett 186 (2002) 59-65
28. Okochi O., Hibi K., Sakai M., Inoue S., Takeda S., Kaneko T., and Nakao A. Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. Clin Cancer Res 9 (2003) 5295-5298
29. Grisham J.W. Interspecies comparison of liver carcinogenesis. implications for cancer risk assessment. Carcinogenesis 18 (1997) 59-81
30. Laird P.W., Zijderveld A., Linders K., Rudnicki M.A., Jaenisch R., and Berns A. Simplified mammalian DNA isolation procedure. Nucleic Acids Res 19 (1991) 4293
31. Hesson L., Bieche I., Krex D., Criniere E., Hoang-Xuan K., Maher E.R., and Latif F. Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene 23 (2004) 2408-2419
32. Xiong Z., and Laird P.W. COBRA. a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25 (1997) 2532-2534
33. Santoni-Rugiu E., Jensen M.R., and Thorgeirsson S.S. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha. Cancer Res 58 (1998) 123-134
34. Song M.S., Song S.J., Ayad N.G., Chang J.S., Lee J.H., Hong H.K., Lee H., Choi N., Kim J., Kim H., Kim J.W., Choi E.J., Kirschner M.W., and Lim D.S. The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 6 (2004) 129-137
35. Vos M.D., Ellis C.A., Elam C., Ulku A.S., Taylor B.J., and Clark G.J. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem 278 (2003) 28045-28051
36. Jiang W., Kahn S.M., Guillem J.G., Lu S.H., and Weinstein I.B. Rapid detection of ras oncogenes in human tumors. applications to colon, esophageal, and gastric cancer. Oncogene 4 (1989) 923-928
37. Lee J.S., and Thorgeirsson S.S. Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer. Hepatology 35 (2002) 1134-1143
38. Park H.S., Kim M.S., Huh S.H., Park J., Chung J., Kang S.S., and Choi E.J. Akt (protein kinase B) negatively regulates SEK1 by means of protein phosphorylation. J Biol Chem 277 (2002) 2573-2578
39. Schuringa J.J., Dekker L.V., Vellenga E., and Kruijer W. Sequential activation of Rac-1, SEK-1/MKK-4, and protein kinase C δ is required for interleukin-6-induced STAT3 Ser-727 phosphorylation and transactivation. J Biol Chem 276 (2001) 27709-27715
40. Arbuthnot P., Capovilla A., and Kew M. Putative role of hepatitis B virus X protein in hepatocarcinogenesis. effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways. J Gastroenterol Hepatol 15 (2000) 357-368
41. Yun C., Cho H., Kim S.J., Lee J.H., Park S.Y., Chan G.K., and Cho H. Mitotic aberration coupled with centrosome amplification is induced by hepatitis B virus X oncoprotein via the Ras-mitogen-activated protein/extracellular signal-regulated kinase-mitogen-activated protein pathway. Mol Cancer Res 2 (2004) 159-169
42. Yoshida T., Hanada T., Tokuhisa T., Kosai K., Sata M., Kohara M., and Yoshimura A. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med 196 (2002) 641-653
43. Hayashi J., Aoki H., Kajino K., Moriyama M., Arakawa Y., and Hino O. Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor α. Hepatology 32 (2000) 958-961
44. Lee J.S., Chu I.S., Heo J., Calvisi D.F., Sun Z., Roskams T., Durnez A., Demetris A.J., and Thorgeirsson S.S. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40 (2004) 667-676
45. Dammann R., Schagdarsurengin U., Liu L., Otto N., Gimm O., Dralle H., Boehm B.O., Pfeifer G.P., and Hoang-Vu C. Frequent RASSF1A promoter hypermethylation and K-Ras mutations in pancreatic carcinoma. Oncogene 22 (2003) 3806-3812
46. van Engeland M., Roemen G.M., Brink M., Pachen M.M., Weijenberg M.P., de Bruine A.P., Arends J.W., van den Brandt P.A., de Goeij A.F., and Herman J.G. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene 21 (2002) 3792-3795
47. Li J., Zhang Z., Dai Z., Popkie A.P., Plass C., Morrison C., Wang Y., and You M. RASSF1A promoter methylation and Kras2 mutations in non small cell lung cancer. Neoplasia 5 (2003) 362-366
48. Irimia M., Fraga M.F., Sanchez-Cespedes M., and Esteller M. CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer. Oncogene 23 (2004) 8695-8699
49. Liu L., Tommasi S., Lee D.H., Dammann R., and Pfeifer G.P. Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene 22 (2004) 8125-8136
50. Dallol A., Agathanggelou A., Fenton S.L., Ahmed-Choudhury J., Hesson L., Vos M.D., Clark G.J., Downward J., Maher E.R., and Latif F. RASSF1A interacts with microtubule-associated proteins and modulates microtubule dynamics. Cancer Res 64 (2004) 4112-4116
51. Vos M.D., Martinez A., Elam C., Dallol A., Taylor B.J., Latif F., and Clark G.J. A role for the RASSF1A tumor suppressor in the regulation of Tubulin polymerization and genomic stability. Cancer Res 64 (2004) 4244-4250
52. Aoyama Y., Avruch J., and Zhang X.F. Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases. Oncogene 23 (2004) 3426-3433
53. Yoshida T., Ogata H., Kamio M., Joo A., Shiraishi H., Tokunaga Y., Sata M., Nagai H., and Yoshimura A. SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis. J Exp Med 199 (2004) 1701-1707
54. Scharf J.G., and Braulke T. The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res 35 (2003) 685-693
55. Niwa Y., Kanda H., Shikauchi Y., Saiura A., Matsubara K., Kitagawa T., Yamamoto J., Kubo T., and Yoshikawa H. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 24 (2005) 6406-6417
56. Trikha M., Corringham R., Klein B., and Rossi J.F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer. a review of the rationale and clinical evidence. Clin Cancer Res 9 (2003) 4653-4665
57. Tilg H., Wilmer A., Vogel W., Herold M., Nolchen B., Judmaier G., and Huber C. Serum levels of cytokines in chronic liver diseases. Gastroenterology 103 (1992) 264-274